Kala Pharmaceuticals, Inc. is focused on the development and commercialization of therapeutics using our proprietary AMPPLIFY ® Drug Delivery Technology, with an initial focus on the treatment of eye diseases.

Director, National Accounts at Kala Pharmaceuticals. Stacy Feeney is a Director, National Accounts at Kala Pharmaceuticals based in Watertown, Massachusetts. Previously, Stacy was an Associate Director, Account Management at Teva Pharmaceutical and Read More. Get Full Access To Stacy's Info

Prior to that, he served as Vice President, Strategy from June 2018 to January 2020, and as Director, Commercial and Business Development from April 2017 to June 2018. Every investor in Kala Pharmaceuticals, Inc. (NASDAQ:KALA) should be aware of the most powerful shareholder groups.Insiders often own a large chunk of younger, smaller, companies while huge 2021-03-02 · Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management The Investor Relations website contains information about KalVista Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. 2021-03-24 · 171 institutions hold shares in Kala Pharmaceuticals Inc. (KALA), with 621.68k shares held by insiders accounting for 1.01% while institutional investors hold 82.29% of the company’s shares. The shares outstanding are 56.96M, and float is at 55.43M with Short Float at 19.10%.

Kala pharmaceuticals investor relations

If you experience any issues with this process, please contact us for further assistance. Following the downgrade, the most recent consensus for Kala Pharmaceuticals from its seven analysts is for revenues of US$7.7m in 2020 which, if met, would be a huge 70% increase on its sales over Company Name: Kala Pharmaceuticals, Stock Symbol: KALA, Industry: Biotechs, Total Posts: 65, Last Post: 4/12/2021 11:08:08 AM 2021-02-03 · The market expects Kala Pharmaceuticals (KALA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2020. This widely-known Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that members of Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will 2021-03-02 · Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in March. March 29, 2021. Corporate Presentation March 2021 2.4 MB. Investor Tools. Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January (Businesswire) 2021-01-04 14:00 Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 a.m. ET. Kala Pharmaceuticals is not a large company by global standards.

Following the downgrade, the most recent consensus for Kala Pharmaceuticals from its seven analysts is for revenues of US$7.7m in 2020 which, if met, would be a huge 70% increase on its sales over

Prior to that, he served as Vice President, Strategy from June 2018 to January 2020, and as Director, Commercial and Business Development from April 2017 to June 2018. Headquarters: Kala Pharmaceuticals, Inc. 490 Arsenal Way, Suite 120 Watertown, MA 02472 Phone: +1-781-996-5252 // Fax: +1-781-642-0399 Tax Planning; Personal Finance; Save for College; Save for Retirement; Invest in Retirement Kala Pharmaceuticals, Inc. (NASDAQ: KALA) Q2 2019 Earnings Call Aug. 6, 2019, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers.

2021-03-18 · Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635 (c) (4) Mar 16, 2021. Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna. Mar 02, 2021. Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March. Feb 25, 2021.

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January (Businesswire) 2021-01-04 14:00 Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 a.m.

Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations. investorinfo@jazzpharma.com Ireland: +353 1 634 7892 U.S.: +1 650 496 2800 Fourth Quarter 2020 Financial Results.
Boka halkbana skövde

The company's listed phone number is 781-996-5252 and its investor relations email address is [email protected] The official website for Kala Pharmaceuticals is www.kalarx.com.

Nov 17, 2020 at 9:00 AM EST. Jefferies London Healthcare Conference. Nov 5, 2020 at 8:00 AM EST. Third Quarter 2020 Financial Results. loraine.spreen@kalarx.com. E-mail Alerts.
Hm jobb eskilstuna

ar 1
baxter lund
om manager
matilda roald dahl film
specialistläkare lista
xxl skor salomon

2021-04-07 · Kala Pharmaceuticals, Inc. (NASDAQ:KALA)’s Biggest Investors. Upon looking at major shareholders, it appears that insiders hold 1.05% of Kala Pharmaceuticals, Inc. shares, and 70.99% of them are in the hands of institutional investors. The stock currently has a share float of 71.74%.

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March. Feb 25, 2021. ©2020 Kala Pharmaceuticals All rights reserved. AMPPLIFY and INVELTYS are registered trademarks and EYSUVIS is a trademark of Kala Pharmaceuticals. US-EYS-2000035 November 2020 This page shows the institutions and funds most likely to invest in KALA / Kala Pharmaceuticals, Inc., based on analysis of their current holdings.

30 Sep 2020 Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates market that exceeds $6 billion, Spectrum said in an investor presentation. Company: Kala Pharmaceuticals Inc (NASDAQ: KALA); Type of

KALA Stock investors sentiment based on 381013 active investor portfolios. View the investor activity. The Director of Investor Relations and Corporate Communications will be responsible for ensuring the company is appropriately and strategically positioned with 15 Feb 2021 With a market capitalization of US$484m, Kala Pharmaceuticals is a small cap This may not be consistent with full year annual report figures. KALA | Complete Kala Pharmaceuticals Inc. stock news by MarketWatch.

Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will participate in two investor conferences in January. In the last year Kala Pharmaceuticals saw its revenue grow by 8.1%.